---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-028715"
form_type: "8-K"
ticker: "XAIR"
cik: "0001641631"
company_name: "Beyond Air, Inc."
filed_at: "2023-08-15T23:59:59+00:00"
generated_at: "2026-06-11T09:27:00.410401+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Beyond Air Q1 FY2024 revenue $0.1M (first commercial); net loss $14.1M; secured $40M debt facility

## Summary
- Revenue of $0.1M from commercial LungFit PH sales; cost of revenue $0.3M.
- Net loss $14.1M ($0.45 loss per share) vs $10.9M ($0.37) YoY; R&D $4.7M, G&A $10.9M.
- Secured up to $40M debt financing from Avenue Capital; $17.5M drawn; cash $57M.
- In excess of $1M annual commercial LungFit PH contracts; CE Mark expected by end 2023.
- Agreed with FDA on VCAP study for 2023-24 winter; added nNOS program for autism.

## SEC filing metadata
- accession: 0001493152-23-028715
- form_type: 8-K
- ticker: XAIR
- cik: 0001641631
- company_name: Beyond Air, Inc.
- filed_at: 2023-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641631/000149315223028715/0001493152-23-028715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641631/000149315223028715/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-028715
- JSON: https://secwatch.observer/filing/0001493152-23-028715.json
- Plain text: https://secwatch.observer/filing/0001493152-23-028715.txt

## Key facts
- Earnings Releases
  Beyond Air, Inc. reported the fiscal quarter ended June 30, 2023 results: revenue $0.1 million, net income ($14.1) million, EPS ($0.45) per share, basic and diluted.
  - Period: the fiscal quarter ended June 30, 2023
  - Revenue: $0.1 million
  - Net income: ($14.1) million
  - EPS: ($0.45) per share, basic and diluted
  - Result: reported results
  source text: a first-in-human study of nNOS for treatment of ASD in 2025 Financial Results for the Fiscal Quarter Ended June 30, 2023 Revenues for the three months ended June 30, 2023 were $0.1 million compared to zero for the quarter ended June 30, 2022. Cost of revenue of $0.3 million was recognized for the three months ended June 30, 2023, compared to $0 for the three months
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641631/000149315223028715/0001493152-23-028715-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.